Overview

A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer

Status:
Recruiting
Trial end date:
2027-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of KC1036 versus investigator's choice of chemotherapy in patients with advanced recurrent or metastatic esophageal squamous cell carcinoma
Phase:
Phase 3
Details
Lead Sponsor:
Beijing Konruns Pharmaceutical Co., Ltd.
Treatments:
Docetaxel
Irinotecan
Tegafur